This study is to assess the impact on the prevention of sarcopenia after taking cetylpyridinium chloride targeting the patients of presarcopenia over the age of 60.
65 people that meet the inclusion criteria on screening test are assigned to one of five groups by randomization. They take the medication for two weeks under double-blind. Four study groups take cetylpyridinium chloride of 1.5mg, 3mg, 4.5mg and 6mg daily for two weeks. Control group takes the placebo for the same period. The main outcome variables are measured and compared respectively in baseline, immediately after dosing end and two weeks after the end of administration. Finally cetylpyridinium chloride is verified whether it has a preventive effect on sarcopenia and set an appropriate dose.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
65
Four study groups take cetylpyridinium chloride of 1.5mg, 3mg, 4.5mg and 6mg daily for two weeks.
Control group takes the placebo for the same period.
Change from baseline in procollagen type III N-terminal peptide
Time frame: baseline, immediately after dosing end, two weeks after the end of administration
Change from baseline in myostatin
Time frame: baseline, immediately after dosing end, two weeks after the end of administration
Change from baseline in TNF-α
Time frame: baseline, immediately after dosing end, two weeks after the end of administration
Change from baseline in IL-6
Time frame: baseline, immediately after dosing end, two weeks after the end of administration
Change from baseline in urinary creatinine
Time frame: baseline, immediately after dosing end, two weeks after the end of administration
Change from baseline in CRP
Time frame: baseline, immediately after dosing end, two weeks after the end of administration
Change from baseline in Hemoblobin
Time frame: baseline, immediately after dosing end, two weeks after the end of administration
Change from baseline in Albumin
Time frame: baseline, immediately after dosing end, two weeks after the end of administration
Change from baseline in Vitamin D
Time frame: baseline, immediately after dosing end, two weeks after the end of administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.